One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients

BACKGROUND: Despite treatment guidance endorsing shortened dual antiplatelet therapy (DAPT) duration in high bleeding risk (HBR) patients after drug-eluting stents, limited evidence exists to support these recommendations. The present study was designed to examine the safety and effectiveness of 1-m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circ Cardiovasc Interv
Hlavní autoři: Kandzari, David E., Kirtane, Ajay J., Windecker, Stephan, Latib, Azeem, Kedhi, Elvin, Mehran, Roxana, Price, Matthew J., Abizaid, Alexandre, Simon, Daniel I., Worthley, Stephen G., Zaman, Azfar, Choi, James W., Caputo, Ronald, Kanitkar, Mihir, McLaurin, Brent, Potluri, Srinivasa, Smith, Timothy, Spriggs, Douglas, Tolleson, Thaddeus, Nazif, Tamim, Parke, Maria, Lee, Lilian C., Lung, Te-Hsin, Stone, Gregg W.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7665241/
https://ncbi.nlm.nih.gov/pubmed/33167705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.009565
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky